Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 6, 2014, Pages 760-769

  van der Zouwen, Boris ^a   Kruisselbrink, Alwine B ^a   Frederik Falkenburg, J H ^a   Jedema, Inge ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Allogeneic stem cell transplantation; Collateral damage; Graft versus host disease; Minor histocompatibility antigen; T cell

Indexed keywords

GRANZYME B; MINOR HISTOCOMPATIBILITY ANTIGEN; EPITOPE; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN;

APOPTOSIS; ARTICLE; COMPLEX FORMATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIESIS; HEMATOPOIETIC CELL; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE INJURY; ADVERSE EFFECTS; CONFOCAL MICROSCOPY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FIBROBLAST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; PATHOLOGY; PROCEDURES;

EPITOPES, T-LYMPHOCYTE; FEMALE; FIBROBLASTS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-A2 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MICROSCOPY, CONFOCAL; MINOR HISTOCOMPATIBILITY ANTIGENS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84899901953     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.03.002     Document Type: Article

References (45)

1. Appelbaum F.R. The current status of hematopoietic cell transplantation. Annu Rev Med 2003, 54:491-512.
2. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
3. Falkenburg J.H., van de Corput L., Marijt E.W., Willemze R. Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol 2003, 31:743-751.
4. Feng X., Hui K.M., Younes H.M., Brickner A.G. Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses. Trends Immunol 2008, 29:624-632.
5. Mullally A., Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 2007, 109:1355-1362.
6. Irle C., Beatty P.G., Mickelson E., et al. Alloreactive T cell responses between HLA-identical siblings: detection of anti-minor histocompatibility T cell clones induced in vivo. Transplantation 1985, 40:329-333.
7. Riddell S.R., Murata M., Bryant S., Warren E.H. Minor histocompatibility antigens: targets of graft-versus-leukemia responses. Int J Hematol 2002, 76(Suppl 2):155-161.
8. Riddell S.R., Berger C., Murata M., et al. The graft-versus-leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev 2003, 17:153-162.
9. Aglietta M., Piacibello W., Stacchini A., et al. Expression of HLA class II (DR, DQ) determinants by normal and chronic myeloid leukemia granulocyte/monocyte progenitors. Cancer Res 1986, 46(4 Pt 1):1783-1787.
10. Ibisch C., Gallot G., Vivien R., et al. Recognition of leukemic blasts by HLA-DPB1-specific cytotoxic T cell clones: a perspective for adjuvant immunotherapy post-bone marrow transplantation. Bone Marrow Transplant 1999, 23:1153-1159.
11. Rutten C.E., van Luxemburg-Heijs S.A., Griffioen M., et al. HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia. Leukemia 2008, 22:1387-1394.
12. Goulmy E., Schipper R., Pool J., et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996, 334:281-285.
13. Tseng L.H., Lin M.T., Hansen J.A., et al. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1999, 94:2911-2914.
14. Dickinson A.M., Wang X.N., Sviland L., et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002, 8:410-414.
15. Lanzavecchia A. Is the T-cell receptor involved in T-cell killing?. Nature 1986, 319:778-780.
16. Gagnon S.J., Ennis F.A., Rothman A.L. Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones. J Virol 1999, 73:3623-3629.
17. + cytotoxic T lymphocytes. J Virol 1998, 72:5948-5954.
18. Staege M.S., Schneider J., Eulitz M., et al. Consequences of antigen self-presentation by tumor-specific cytotoxic T cells. Immunobiology 2000, 201:332-346.
19. Gremion C., Grabscheid B., Wolk B., et al. Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. J Virol 2004, 78:2152-2157.
20. + CTL. J Immunol 1997, 159:2728-2734.
21. Smyth M.J. Fas ligand-mediated bystander lysis of syngeneic cells in response to an allogeneic stimulus. J Immunol 1997, 158:5765-5772.
22. + cytotoxic T lymphocytes. Eur J Immunol 1998, 28:4162-4169.
23. + T helper 1 effectors. J Immunol 1996, 157:2961-2968.
24. Ando K., Hiroishi K., Kaneko T., et al. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 1997, 158:5283-5291.
25. Kuwano K., Arai S. Involvement of two distinct killing mechanisms in bystander target cell lysis induced by a cytotoxic T lymphocyte clone. Cell Immunol 1996, 169:288-293.
26. van der Zouwen B., Kruisselbrink A.B., Jordanova E.S., et al. Alloreactive effector T cells require the local formation of a proinflammatory environment to allow crosstalk and high-avidity interaction with nonhematopoietic tissues to induce GVHD reactivity. Biol Blood Marrow Transplant 2012, 18:1353-1367.
27. de Vries J.F., von dem Borne P.A., van Luxemburg-Heijs S.A., et al. Differential activation of the death receptor pathway in human target cells induced by cytotoxic T lymphocytes showing different kinetics of killing. Haematologica 2007, 92:1671-1678.
28. de Vries J.F., Wammes L.J., Jedema I., et al. Involvement of caspase-8 in chemotherapy-induced apoptosis of patient derived leukemia cell lines independent of the death receptor pathway and downstream from mitochondria. Apoptosis 2007, 12:181-193.
29. Heemskerk M.H., de Paus R.A., Lurvink E.G., et al. Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proc Natl Acad Sci USA 2001, 98:6806-6811.
30. Jonuleit H., Kuhn U., Muller G., et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997, 27:3135-3142.
31. Lee A.W., Truong T., Bickham K., et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 2002, 20(Suppl 4):A8-A22.
32. Nijmeijer B.A., Szuhai K., Goselink H.M., et al. Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors. Exp Hematol 2009, 37:376-385.
33. van Bergen C.A., Kester M.G., Jedema I., et al. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. Blood 2007, 109:4089-4096.
34. Meadows L., Wang W., den Haan J.M., et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 1997, 6:273-281.
35. Kloosterboer F.M., van Luxemburg-Heijs S.A., van Soest R.A., et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1- and HA-2-specific T cells. Leukemia 2004, 18:798-808.
36. + T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia. Leukemia 2012, 26:312-322.
37. Altman J.D., Moss P.A., Goulder P.J., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996, 274:94-96.
38. +-dependent apoptosis. Blood 2008, 111:2354-2363.
39. Scaffidi C., Medema J.P., Krammer P.H., Peter M.E. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J Biol Chem 1997, 272:26953-26958.
40. English L., Chemali M., Duron J., et al. Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection. Nat Immunol 2009, 10:480-487.
41. Smyth L.A., Harker N., Turnbull W., et al. The relative efficiency of acquisition of MHC:peptide complexes and cross-presentation depends on dendritic cell type. J Immunol 2008, 181:3212-3220.
42. Rock K.L., Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev 2005, 207:166-183.
43. Berg N.N., Ostergaard H.L. Characterization of intercellular adhesion molecule-1 (ICAM-1)-augmented degranulation by cytotoxic T cells: ICAM-1 and anti-CD3 must be co-localized for optimal adhesion and stimulation. J Immunol 1995, 155:1694-1702.
44. Symington F.W., Santos E.B. Lysis of human keratinocytes by allogeneic HLA class I-specific cytotoxic T cells: keratinocyte ICAM-1 (CD54) and T cell LFA-1 (CD11a/CD18) mediate enhanced lysis of IFN-γ-treated keratinocytes. J Immunol 1991, 146:2169-2175.
45. Ferrara J.L. Cytokine dysregulation as a mechanism of graft-versus-host disease. Curr Opin Immunol 1993, 5:794-799.